Pfizer: new efficacy data in Covid-19

(CercleFinance.com) - Pfizer and BioNTech announce updated first-line results from the analysis of 927 confirmed symptomatic cases of Covid-19, showing that their BNT162b2 vaccine is 91.
3% effective, measured up to six months after the second dose.

The vaccine is 100%-effective against severe diseases, as defined by US CDCs (Centers for Disease Control and Prevention) and 95.3% effective against severe Covid-19 as defined by the US FDA, as well as 100%-effective in preventing Covid-19 cases in South Africa, where the B.1.351 lineage is prevalent.

Safety data from the Phase III study were also collected from over 12,000 vaccinated participants who have a minimum of six months of follow-up after the second dose, demonstrating a favourable safety and tolerability profile.


Copyright (c) 2021 CercleFinance.com. All rights reserved.